Business
Scancell member of team shortlisted for CRUK award
Scancell member of team shortlisted for CRUK award.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2383E Scancell Holdings Plc 08 February 2018 \n\n8 February 2018\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell a member of high profile team shortlisted for Cancer Research UK's prestigious Grand Challenge award\n \n \nHighlights\n \n· Grand Challenge award recognises research proposals that tackle some of the toughest questions in cancer\n· Team's proposal seeks to leverage a tumour vaccine approach to build a blueprint for effective personalised therapies for patients with most types of cancer\n· Prof. Lindy Durrant, Chief Scientific Officer of Scancell, to lead the multidisciplinary team of eminent cancer immunotherapy scientists, in partnership with leading biotechnology companies\n· Novel vaccine candidates generated from Scancell's proprietary Moditope® platform form central element of approach\n· Shortlisting of proposal represents a significant scientific endorsement of Scancell's technology\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is proud to announce that an international, multi-disciplinary team of the leading cancer immunotherapy scientists in Europe and the US, led by Prof. Lindy Durrant, Chief Scientific Officer of Scancell, and in partnership with Genentech, BioNtech and ISA pharmaceuticals1, has been shortlisted to the final stages of Cancer Research UK's Grand Challenge2 - an ambitious series of £20 million global grants tackling some of the toughest questions in cancer research. The team will collaborate on a project entitled \"Project Blueprint: Eradicating established tumours with unique cancer vaccines\".\n \nThe Grand Challenge award aims to revolutionise how cancer is diagnosed, prevented and/or treated by providing international multi-disciplinary teams the freedom to evaluate novel approaches, at scale, in the pursuit of life changing discoveries.\n \nProject Blueprint aims to eliminate tumours by treating patients with specific vaccines. Prof. Lindy Durrant will lead an international world-class team to investigate the full potential of the tumour vaccine concept by ...